OBJECTIVES: With increasing complexity of critical care medicine comes an increasing need for multidisciplinary involvement in care. In many institutions, pharmacists are an integral part of this team, but long-term data on the interventions performed by pharmacists and their effects on patient care and outcomes are limited. We aimed to describe the role of pediatric clinical pharmacists in pediatric intensive care unit (PICU) practice. METHODS: We retrospectively reviewed the records of pharmacy interventions in the PICU at the Mayo Clinic in Rochester, Minnesota, from 2003-2013, with a distinct period of increased pharmacist presence in the PICU from 2008 onward. We compared demographic and outcome data on patients who did and who did not have pharmacy interventions during 2 periods (2003-2007 and 2008-2013). RESULTS: We identified 27,773 total interventions by pharmacists during the 11-year period, of which 79.8% were accepted by the clinical team. These interventions were made on 10,963 unique PICU admissions and prevented 5867 order entry errors. Pharmacists' interventions increased year over year, including a significant change in 2008. Patients who required pharmacy involvement were younger, sicker, and had longer intensive care unit, hospital, and ventilator duration. Average central line infections and central line entry rates decreased significantly over the study period. CONCLUSIONS: Increased pharmacist presence in the PICU is associated with increased interventions and prevention of adverse drug events. Pharmacist participation during rounds and order entry substantially improved the care of critically sick children and should be encouraged.
OBJECTIVES: With increasing complexity of critical care medicine comes an increasing need for multidisciplinary involvement in care. In many institutions, pharmacists are an integral part of this team, but long-term data on the interventions performed by pharmacists and their effects on patient care and outcomes are limited. We aimed to describe the role of pediatric clinical pharmacists in pediatric intensive care unit (PICU) practice. METHODS: We retrospectively reviewed the records of pharmacy interventions in the PICU at the Mayo Clinic in Rochester, Minnesota, from 2003-2013, with a distinct period of increased pharmacist presence in the PICU from 2008 onward. We compared demographic and outcome data on patients who did and who did not have pharmacy interventions during 2 periods (2003-2007 and 2008-2013). RESULTS: We identified 27,773 total interventions by pharmacists during the 11-year period, of which 79.8% were accepted by the clinical team. These interventions were made on 10,963 unique PICU admissions and prevented 5867 order entry errors. Pharmacists' interventions increased year over year, including a significant change in 2008. Patients who required pharmacy involvement were younger, sicker, and had longer intensive care unit, hospital, and ventilator duration. Average central line infections and central line entry rates decreased significantly over the study period. CONCLUSIONS: Increased pharmacist presence in the PICU is associated with increased interventions and prevention of adverse drug events. Pharmacist participation during rounds and order entry substantially improved the care of critically sick children and should be encouraged.
Entities:
Keywords:
adverse drug reaction; catheter-related infections; medication errors; pediatric intensive care units; pharmacists
Authors: Rainu Kaushal; David W Bates; Erika L Abramson; Jane R Soukup; Donald A Goldmann Journal: Am J Health Syst Pharm Date: 2008-07-01 Impact factor: 2.637
Authors: T C Bailey; D J Ritchie; S T McMullin; M Kahn; R M Reichley; E Casabar; W Shannon; W C Dunagan Journal: Pharmacotherapy Date: 1997 Mar-Apr Impact factor: 4.705
Authors: A Soubieux; C Chenailler; C Lattard; C Banse; M Kozyreff-Meurice; H Gondé; T Lequerré; O Vittecoq; R Varin Journal: Clin Rheumatol Date: 2020-06-09 Impact factor: 2.980
Authors: Lorena Michele Brennan-Bourdon; Alan O Vázquez-Alvarez; Jahaira Gallegos-Llamas; Manuel Koninckx-Cañada; José Luis Marco-Garbayo; Selene G Huerta-Olvera Journal: BMC Pediatr Date: 2020-12-05 Impact factor: 2.125